Oxbow Advisors LLC Has $566,000 Stock Position in Eli Lilly and Company $LLY

Oxbow Advisors LLC reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 23.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 727 shares of the company’s stock after selling 218 shares during the period. Oxbow Advisors LLC’s holdings in Eli Lilly and Company were worth $566,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Nordea Investment Management AB raised its position in Eli Lilly and Company by 6.3% during the second quarter. Nordea Investment Management AB now owns 1,294,391 shares of the company’s stock valued at $1,010,544,000 after purchasing an additional 77,020 shares in the last quarter. Commons Capital LLC increased its holdings in shares of Eli Lilly and Company by 17.5% during the second quarter. Commons Capital LLC now owns 618 shares of the company’s stock worth $482,000 after buying an additional 92 shares in the last quarter. S Bank Fund Management Ltd increased its holdings in shares of Eli Lilly and Company by 111.9% during the second quarter. S Bank Fund Management Ltd now owns 19,932 shares of the company’s stock worth $15,538,000 after buying an additional 10,527 shares in the last quarter. Harbor Asset Planning Inc. acquired a new position in shares of Eli Lilly and Company during the second quarter worth $156,000. Finally, Werba Rubin Papier Wealth Management increased its holdings in shares of Eli Lilly and Company by 11.9% during the second quarter. Werba Rubin Papier Wealth Management now owns 603 shares of the company’s stock worth $470,000 after buying an additional 64 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $818.45 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The stock has a market cap of $774.63 billion, a price-to-earnings ratio of 53.49, a P/E/G ratio of 1.18 and a beta of 0.47. The company’s fifty day moving average is $749.52 and its 200 day moving average is $766.23.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the firm posted $3.92 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Berenberg Bank reiterated a “hold” rating and set a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Finally, UBS Group lowered their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $939.12.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director Jamere Jackson purchased 200 shares of the business’s stock in a transaction on Friday, August 8th. The shares were acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares of the company’s stock, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David A. Ricks purchased 1,632 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the transaction, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.